- Cash and equivalents declined to $52 million from $109.1 million at year-end 2024.
- Gross to net provisions improved to 26.8% in Q2 2025 from 45% in Q1 2025 and 29.3% in Q2 2024, driven by mix and lower 340B discounts.
- Interest expense increased to $11.2 million from $8.9 million due to refinancing impacts.
- Net loss was $37.3 million or $4.32 per share, including $11.2 million interest expense and $2 million noncash losses from warrant and derivative remeasurement.
- R&D expenses decreased 15% to $32.8 million due to headcount reductions and lower clinical trial costs.
- SG&A expenses decreased 8% to $28.5 million reflecting cost reduction initiatives.
- Total revenue for Q2 2025 was $37.9 million, down from $42.8 million in Q2 2024, primarily due to $6 million of nonrecurring license revenue in 2024.
- U.S. XPOVIO net product revenue increased 6% year-over-year to $29.7 million in Q2 2025.
Related items and other data are not available for this feed item.
Dafinchi